Michael Shetzline, SVP, CMO, and Head of Research and Drug Development at Ironwood Pharmaceuticals Inc. ($IRWD), sold shares on the open market twice in the last 365 days for a total of about $122,000. His most recent sale occurred on February 24, 2026. These sales rank him 9,290th among 11,678 individual insiders by amount sold, well below the average of $8.6 million across about 6.4 transactions per insider. Shetzline made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 10, 2026 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | A | Class A Common Stock | 136612 | $0.00 | 658,037.0000 | 162,983,000 | 26.20% | 0.08% |
| Feb. 24, 2026 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | S | Common Stock | 17012 | $3.66 | 521,425.0000 | 162,983,000 | 3.37% | 0.01% |
| Feb. 23, 2026 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | S | Class A Common Stock | 15570 | $3.81 | 538,437.0000 | 162,983,000 | 2.81% | 0.01% |
| Feb. 10, 2025 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | A | Class A Common Stock | 133333 | $0.00 | 595,276.0000 | 160,084,000 | 28.86% | 0.08% |
| Feb. 10, 2025 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | S | Class A Common Stock | 41269 | $1.76 | 554,007.0000 | 160,084,000 | 6.93% | 0.03% |
| Jan. 17, 2025 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | A | Class A Common Stock | 48224 | $0.00 | 461,943.0000 | 160,084,000 | 11.66% | 0.03% |
| May 20, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 16128 | $6.45 | 413,719.0000 | 157,700,000 | 3.75% | 0.01% |
| March 8, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | M | Performance-based Restricted Stock Unit | 34936 | $0.00 | 0.0000 | 155,435,000 | 100.00% | 0.02% |
| March 8, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | M | Class A Common Stock | 34936 | $0.00 | 429,847.0000 | 155,435,000 | 8.85% | 0.02% |
| Feb. 12, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 38618 | $15.24 | 340,484.0000 | 155,435,000 | 10.19% | 0.02% |
| Feb. 12, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | A | Performance-based Restricted Stock Unit | 27214 | $0.00 | 27,214.0000 | 155,435,000 | 9999.99% | 0.02% |
| Feb. 12, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | A | Class A Common Stock | 54427 | $0.00 | 394,911.0000 | 155,435,000 | 15.99% | 0.04% |
| Jan. 17, 2024 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | A | Class A Common Stock | 57971 | $0.00 | 379,102.0000 | 155,435,000 | 18.05% | 0.04% |
| May 22, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 10324 | $10.12 | 321,131.0000 | 186,680,000 | 3.11% | 0.01% |
| March 8, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | A | Performance-based Restricted Stock Units | 34935 | $0.00 | 34,935.0000 | 186,312,000 | 9999.99% | 0.02% |
| March 8, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | A | Class A Common Stock | 69869 | $0.00 | 331,455.0000 | 186,312,000 | 26.71% | 0.04% |
| Feb. 28, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 2416 | $11.31 | 261,586.0000 | 186,312,000 | 0.92% | 0.00% |
| Feb. 27, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 7146 | $11.41 | 273,762.0000 | 186,312,000 | 2.54% | 0.00% |
| Feb. 27, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 2322 | $11.41 | 271,440.0000 | 186,312,000 | 0.85% | 0.00% |
| Feb. 28, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | S | Class A Common Stock | 7438 | $11.31 | 264,002.0000 | 186,312,000 | 2.74% | 0.00% |
| Jan. 17, 2023 | IRONWOOD PHARMACEUTICALS INC | $IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | A | Class A Common Stock | 14663 | $0.00 | 280,908.0000 | 186,312,000 | 5.51% | 0.01% |